Hochman David P 4

What Happened
David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed (OBIO), made an open-market purchase of 10,000 shares on March 13, 2026. The reported weighted-average price was $4.29 per share, for a total cost of approximately $42,900. This transaction is a straight purchase (code P), not an option exercise or award.

Key Details

• Transaction date: 2026-03-13 (reported on Form 4 filed 2026-03-16). Filing appears timely.
• Price: weighted average $4.29; purchases occurred in multiple trades at prices ranging $4.28–$4.30 (see footnote).
• Shares acquired: 10,000; total consideration ≈ $42,900.
• Shares owned after transaction: not specified in the information provided.
• Footnote: weighted-average price reported; the filer can provide a breakdown of the number of shares bought at each price within the $4.28–$4.30 range upon request.
• Remarks: Reporting person is CEO and Chair; transaction code P = Purchase.

Context
This was a direct open-market purchase by a top executive. Insider purchases can be of interest to investors as one data point about insider willingness to buy, but they are not proof of future company performance. The trade was a modest-sized purchase in dollar terms (~$43k) and was filed within the normal Form 4 timeframe.